Which has preferable valuation and earnings, SRRK or AVBP?

Scholar Rock is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A ArriVent BioPharma N/A N/A -$166.31M -$3.47 N/A

Is SRRK or AVBP more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% ArriVent BioPharma N/A -48.98% -45.44%

Does the media refer more to SRRK or AVBP?

In the previous week, Scholar Rock had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for Scholar Rock and 1 mentions for ArriVent BioPharma. Scholar Rock's average media sentiment score of 1.57 beat ArriVent BioPharma's score of 1.32 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GRFS or AVBP?

In the previous week, Grifols had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 2 mentions for Grifols and 1 mentions for ArriVent BioPharma. Grifols' average media sentiment score of 1.64 beat ArriVent BioPharma's score of 1.32 indicating that Grifols is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or AVBP?

In the previous week, CRISPR Therapeutics had 16 more articles in the media than ArriVent BioPharma. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.32 beat CRISPR Therapeutics' score of 0.85 indicating that ArriVent BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 11 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AVBP or CGON more profitable?

CG Oncology's return on equity of -23.33% beat ArriVent BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -48.98% -45.44% CG Oncology N/A -23.33% -22.24%

Does the media prefer AVBP or CGON?

In the previous week, CG Oncology had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for CG Oncology and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.32 beat CG Oncology's score of -0.37 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Is AVBP or XENE more profitable?

ArriVent BioPharma's return on equity of -48.98% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ArriVent BioPharma N/A -48.98% -45.44% Xenon Pharmaceuticals N/A -49.23% -46.42%

Does the media prefer AVBP or XENE?

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 2 mentions for Xenon Pharmaceuticals and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.32 beat Xenon Pharmaceuticals' score of 0.85 indicating that ArriVent BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ArriVent BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ArriVent BioPharma (AVBP) Competitors

$30.50 +0.15 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$30.58 +0.07 (+0.25%)

As of 05:11 PM Eastern

Compare

AVBP vs. SRRK, GRFS, CRSP, CGON, and XENE

Should you buy ArriVent BioPharma stock or one of its competitors? MarketBeat compares ArriVent BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ArriVent BioPharma include Scholar Rock (SRRK), Grifols (GRFS), CRISPR Therapeutics (CRSP), CG Oncology (CGON), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry.

How does ArriVent BioPharma compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, Scholar Rock had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for Scholar Rock and 1 mentions for ArriVent BioPharma. Scholar Rock's average media sentiment score of 1.57 beat ArriVent BioPharma's score of 1.32 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ArriVent BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Scholar Rock is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Scholar Rock presently has a consensus price target of $56.00, indicating a potential upside of 27.85%. ArriVent BioPharma has a consensus price target of $43.38, indicating a potential upside of 42.21%. Given ArriVent BioPharma's higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

ArriVent BioPharma's return on equity of -48.98% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Scholar Rock has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Summary

Scholar Rock and ArriVent BioPharma tied by winning 7 of the 14 factors compared between the two stocks.

How does ArriVent BioPharma compare to Grifols?

Grifols (NASDAQ:GRFS) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Grifols has a net margin of 5.54% compared to ArriVent BioPharma's net margin of 0.00%. Grifols' return on equity of 6.21% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
ArriVent BioPharma	N/A	-48.98%	-45.44%

9.5% of ArriVent BioPharma shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Grifols currently has a consensus target price of $10.00, indicating a potential upside of 36.43%. ArriVent BioPharma has a consensus target price of $43.38, indicating a potential upside of 42.21%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe ArriVent BioPharma is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Grifols had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 2 mentions for Grifols and 1 mentions for ArriVent BioPharma. Grifols' average media sentiment score of 1.64 beat ArriVent BioPharma's score of 1.32 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ArriVent BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.59	$454.82M	$0.19	38.58
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Grifols has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Summary

Grifols beats ArriVent BioPharma on 9 of the 16 factors compared between the two stocks.

How does ArriVent BioPharma compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and ArriVent BioPharma (NASDAQ:AVBP) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, CRISPR Therapeutics had 16 more articles in the media than ArriVent BioPharma. MarketBeat recorded 17 mentions for CRISPR Therapeutics and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.32 beat CRISPR Therapeutics' score of 0.85 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	11 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ArriVent BioPharma has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
ArriVent BioPharma	N/A	-48.98%	-45.44%

CRISPR Therapeutics currently has a consensus target price of $65.47, suggesting a potential upside of 26.88%. ArriVent BioPharma has a consensus target price of $43.38, suggesting a potential upside of 42.21%. Given ArriVent BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe ArriVent BioPharma is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.53
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

ArriVent BioPharma has lower revenue, but higher earnings than CRISPR Therapeutics. ArriVent BioPharma is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,417.90	-$581.60M	-$6.22	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Summary

CRISPR Therapeutics beats ArriVent BioPharma on 8 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to CG Oncology?

ArriVent BioPharma (NASDAQ:AVBP) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

CG Oncology has higher revenue and earnings than ArriVent BioPharma. CG Oncology is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
CG Oncology	$4.04M	1,187.64	-$160.99M	-$2.33	N/A

ArriVent BioPharma currently has a consensus target price of $43.38, suggesting a potential upside of 42.21%. CG Oncology has a consensus target price of $81.73, suggesting a potential upside of 50.23%. Given CG Oncology's higher probable upside, analysts clearly believe CG Oncology is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, CG Oncology had 3 more articles in the media than ArriVent BioPharma. MarketBeat recorded 4 mentions for CG Oncology and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.32 beat CG Oncology's score of -0.37 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

ArriVent BioPharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CG Oncology's return on equity of -23.33% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
CG Oncology	N/A	-23.33%	-22.24%

Summary

CG Oncology beats ArriVent BioPharma on 9 of the 15 factors compared between the two stocks.

How does ArriVent BioPharma compare to Xenon Pharmaceuticals?

ArriVent BioPharma (NASDAQ:AVBP) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Xenon Pharmaceuticals had 1 more articles in the media than ArriVent BioPharma. MarketBeat recorded 2 mentions for Xenon Pharmaceuticals and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.32 beat Xenon Pharmaceuticals' score of 0.85 indicating that ArriVent BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ArriVent BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xenon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.5% of ArriVent BioPharma shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 8.6% of ArriVent BioPharma shares are owned by insiders. Comparatively, 4.1% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ArriVent BioPharma's return on equity of -48.98% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-48.98%	-45.44%
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

ArriVent BioPharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

ArriVent BioPharma presently has a consensus price target of $43.38, suggesting a potential upside of 42.21%. Xenon Pharmaceuticals has a consensus price target of $77.20, suggesting a potential upside of 50.75%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

ArriVent BioPharma has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than ArriVent BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A
Xenon Pharmaceuticals	$7.50M	660.06	-$345.91M	-$4.70	N/A

Summary

ArriVent BioPharma beats Xenon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get ArriVent BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVBP vs. The Competition

Export

Metric	ArriVent BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.41B	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-8.79	10.38	20.24	21.95
Price / Sales	N/A	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	4.10	8.04	10.28	6.78
Net Income	-$166.31M	$23.89M	$3.57B	$337.51M
7 Day Performance	-0.59%	-5.97%	-1.43%	-2.72%
1 Month Performance	3.39%	2.78%	3.27%	1.87%
1 Year Performance	29.68%	36.26%	23.37%	26.61%

ArriVent BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVBP ArriVent BioPharma	2.5327 of 5 stars	$30.50 +0.5%	$43.38 +42.2%	+29.0%	$1.41B	N/A	N/A	40	Positive News
SRRK Scholar Rock	3.3551 of 5 stars	$44.68 -5.7%	$56.00 +25.3%	+29.4%	$5.68B	N/A	N/A	140	Positive News
GRFS Grifols	4.5228 of 5 stars	$7.63 -1.4%	$10.00 +31.1%	-13.4%	$5.27B	$8.51B	40.16	25,247	Positive News
CRSP CRISPR Therapeutics	3.0484 of 5 stars	$52.02 -4.0%	$65.47 +25.9%	+23.8%	$5.23B	$3.51M	N/A	460
CGON CG Oncology	2.9046 of 5 stars	$55.53 -6.2%	$81.73 +47.2%	+99.6%	$5.22B	$4.04M	N/A	61	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVBP) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ArriVent BioPharma (AVBP) Competitors

AVBP vs. SRRK, GRFS, CRSP, CGON, and XENE

How does ArriVent BioPharma compare to Scholar Rock?

Summary

How does ArriVent BioPharma compare to Grifols?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Summary

How does ArriVent BioPharma compare to CG Oncology?

Summary

How does ArriVent BioPharma compare to Xenon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ArriVent BioPharma (AVBP) Competitors

AVBP vs. SRRK, GRFS, CRSP, CGON, and XENE

How does ArriVent BioPharma compare to Scholar Rock?

Does the media refer more to SRRK or AVBP?

Which has preferable valuation and earnings, SRRK or AVBP?

Do analysts rate SRRK or AVBP?

Do institutionals & insiders believe in SRRK or AVBP?

Is SRRK or AVBP more profitable?

Which has more volatility & risk, SRRK or AVBP?

Summary

How does ArriVent BioPharma compare to Grifols?

Is GRFS or AVBP more profitable?

Do institutionals and insiders hold more shares of GRFS or AVBP?

Do analysts prefer GRFS or AVBP?

Does the media favor GRFS or AVBP?

Which has preferable valuation & earnings, GRFS or AVBP?

Which has more risk & volatility, GRFS or AVBP?

Summary

How does ArriVent BioPharma compare to CRISPR Therapeutics?

Does the media favor CRSP or AVBP?

Do insiders & institutionals believe in CRSP or AVBP?

Is CRSP or AVBP more profitable?

Do analysts recommend CRSP or AVBP?

Which has better earnings and valuation, CRSP or AVBP?

Which has more risk & volatility, CRSP or AVBP?

Summary

How does ArriVent BioPharma compare to CG Oncology?

Which has stronger earnings and valuation, AVBP or CGON?

Do analysts prefer AVBP or CGON?

Does the media prefer AVBP or CGON?

Which has more risk and volatility, AVBP or CGON?

Do insiders and institutionals hold more shares of AVBP or CGON?

Is AVBP or CGON more profitable?

Summary

How does ArriVent BioPharma compare to Xenon Pharmaceuticals?

Does the media prefer AVBP or XENE?

Do institutionals & insiders hold more shares of AVBP or XENE?

Is AVBP or XENE more profitable?

Which has more volatility and risk, AVBP or XENE?

Do analysts prefer AVBP or XENE?

Which has better valuation and earnings, AVBP or XENE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVBP vs. The Competition

ArriVent BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools